Evidence map›Paper›PMID 36206200›Full record

ArticleBlood advances2022

RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS.

Yi-Jou Huang, Jia-Yu Chen, Ming Yan, Amanda G Davis, Sayuri Miyauchi, Liang Chen, Yajing Hao, Sigrid Katz, Rafael Bejar, Omar Abdel-Wahab and 2 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yi-Jou HuangMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.
Jia-Yu ChenDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA.ORCID 0000-0001-9449-9321
Ming YanMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.
Amanda G DavisMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.ORCID 0000-0003-4356-7480
Sayuri MiyauchiMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.
Liang ChenDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA.ORCID 0000-0002-6748-9416
Yajing HaoDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA.
Sigrid KatzMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.
Rafael BejarMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.ORCID 0000-0002-5603-4598
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Xiang-Dong FuMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.ORCID 0000-0001-5499-8732
Dong-Er ZhangMoores Cancer Center, UC San Diego (UCSD), La Jolla, CA.
UC San Diego Health System · USUniversity of California San Diego · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathologyR01DK098808 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2013 to 2022
$4.8M
NCI NIH HHS P30 CA008748NIDDK NIH HHS R01 DK098808
6 · The paper itself

Abstract

Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematologic malignancies with a propensity to progress to acute myeloid leukemia. Causal mutations in multiple classes of genes have been identified in patients with MDS with some patients harboring more than 1 mutation. Interestingly, double mutations tend to occur in different classes rather than the same class of genes, as exemplified by frequent cooccurring mutations in the transcription factor RUNX1 and the splicing factor SRSF2. This prototypic double mutant provides an opportunity to understand how their divergent functions in transcription and posttranscriptional regulation may be altered to jointly promote MDS. Here, we report a mouse model in which Runx1 knockout was combined with the Srsf2 P95H mutation to cause multilineage hematopoietic defects. Besides their additive and synergistic effects, we also unexpectedly noted a degree of antagonizing activity of single mutations in specific hematopoietic progenitors. To uncover the mechanism, we further developed a cellular model using human K562 cells and performed parallel gene expression and splicing analyses in both human and murine contexts. Strikingly, although RUNX1 deficiency was responsible for altered transcription in both single and double mutants, it also induced dramatic changes in global splicing, as seen with mutant SRSF2, and only their combination induced missplicing of genes selectively enriched in the DNA damage response and cell cycle checkpoint pathways. Collectively, these data reveal the convergent impact of a prototypic MDS-associated double mutant on RNA processing and suggest that aberrant DNA damage repair and cell cycle regulation critically contribute to MDS development.

Indexed as

Core Binding Factor Alpha 2 SubunitMyelodysplastic SyndromesAnimalsHumansMiceMutationRNA SplicingSerine-Arginine Splicing FactorsCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanRunx1 protein, mouseSerine-Arginine Splicing FactorsSRSF2 protein, humanSRSF2 protein, mouse

Identifiers

PMID36206200
PMCPMC9772487
OpenAlexW4303453963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.